Another basket trial including four patients with DNA mismatch repair deficiency (dMMR) cholangiocarcinoma demonstrated that one patient had a complete response (CR) and the other three patients had SD after PD-1 blockade therapy [10]. This evidence concerns the gene PDCD1 and cholangiocarcinoma.